Oxular is Drug Discovery in United Kingdom that focus on diabetic macular edema business. Founded in 2014. They cover business area such as operator, retinal disease, large patient population, tissue-specific delivery, potent drug product, multiple pathophysiological pathway, age-relate macular degeneration, diabetic macular edema, retinal vein occlusion, their therapeutic effectiveness, its side effect, their retinal treatment.
2014
( 12 years old in 2026 )
Diabetic Macular Edema
-
Magdalen Centre
1 Robert Robinson Avenue
Oxford OX4 4GA
England, United Kingdom
Private
operatorretinal diseaselarge patient populationtissue-specific deliverypotent drug productmultiple pathophysiological pathwayage-relate macular degenerationdiabetic macular edemaretinal vein occlusiontheir therapeutic effectivenessits side effecttheir retinal treatment
* We use standard office opening hours in near Oxular's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Oxular is Drug Discovery business from United Kingdom that founded in 2014 (12 years old in 2026), Oxular business is focusing on Diabetic Macular Edema.
Oxular headquarter office and corporate office address is located in Magdalen Centre 1 Robert Robinson Avenue Oxford OX4 4GA England, United Kingdom.
Oxular was founded in United Kingdom.
In 2026, Oxular is currently focus on diabetic macular edema sector.
Above is snippet of Google Trends for "diabetic macular edema" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Oxular, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
